$AMRN
AMARIN CORP PLC\UK Stock $amrn

$amrn Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000119312513326829 Filed on August 08, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$5.500M
YoY Change
Cost Of Revenue	$2.844M
YoY Change
Gross Profit	$2.656M
YoY Change
Gross Profit Margin	48.29%
Selling, General & Admin	$33.96M	$13.64M
YoY Change	149.07%	36.01%
% of Gross Profit	1278.65%
Research & Development	$17.49M	$14.07M
YoY Change	24.34%	171.07%
% of Gross Profit	658.47%
Depreciation & Amortization	$220.0K	$50.00K
YoY Change	340.0%	400.0%
% of Gross Profit	8.28%
Operating Expenses	$51.45M	$27.70M
YoY Change	85.73%	82.08%
Operating Profit	-$48.79M	-$27.70M
YoY Change	76.15%	82.08%
Interest Expense	-$9.345M	-$4.317M
YoY Change	116.47%	4492.55%
% of Operating Profit
Other Income/Expense, Net	-$411.0K	-$52.00K
YoY Change	690.38%	372.73%
Pretax Income	-$39.71M	-$51.00M
YoY Change	-22.14%	-125.44%
Income Tax	$65.00K	$2.904M
% Of Pretax Income
Net Earnings	-$39.77M	-$53.90M
YoY Change	-26.21%	-73.33%
Net Earnings / Revenue	-723.16%
Basic Earnings Per Share	-$0.26	-$0.38
Diluted Earnings Per Share	-$0.34	-$0.38
COMMON SHARES
Basic Shares Outstanding	150.7M shares
Diluted Shares Outstanding	157.0M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$149.4M	$250.3M
YoY Change	-40.31%	90.49%
Cash & Equivalents	$149.4M	$250.3M
Short-Term Investments
Other Short-Term Assets	$2.171M	$6.433M
YoY Change	-66.25%	484.82%
Inventory	$28.51M
Prepaid Expenses
Receivables	$2.267M
Other Receivables	$0.00
Total Short-Term Assets	$184.7M	$257.2M
YoY Change	-28.19%	93.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$706.0K	$621.0K
YoY Change	13.69%	521.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.335M	$2.482M
YoY Change	114.95%	-14.41%
Total Long-Term Assets	$29.95M	$13.95M
YoY Change	114.66%	381.17%
TOTAL ASSETS
Total Short-Term Assets	$184.7M	$257.2M
Total Long-Term Assets	$29.95M	$13.95M
Total Assets	$214.7M	$271.2M
YoY Change	-20.84%	100.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.688M	$8.429M
YoY Change	14.94%	343.63%
Accrued Expenses	$14.40M	$9.100M
YoY Change	58.24%	405.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.600M
YoY Change
Total Short-Term Liabilities	$35.43M	$17.50M
YoY Change	102.49%	360.5%
LONG-TERM LIABILITIES
Long-Term Debt	$86.69M	$127.4M
YoY Change	-31.98%	25387.6%
Other Long-Term Liabilities	$795.0K	$704.0K
YoY Change	12.93%	-99.75%
Total Long-Term Liabilities	$87.48M	$128.1M
YoY Change	-31.73%	-55.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.43M	$17.50M
Total Long-Term Liabilities	$87.48M	$128.1M
Total Liabilities	$309.0M	$265.9M
YoY Change	16.23%	-8.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$849.6M	-$710.6M
YoY Change	19.55%
Common Stock	$755.5M	$716.2M
YoY Change	5.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$217.0K	$217.0K
YoY Change	0.0%
Treasury Stock Shares	20.08K shares	20.08K shares
Shareholders Equity	-$94.33M	$5.320M
YoY Change
Total Liabilities & Shareholders Equity	$214.7M	$271.2M
YoY Change	-20.84%	100.13%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$39.77M	-$53.90M
YoY Change	-26.21%	-73.33%
Depreciation, Depletion And Amortization	$220.0K	$50.00K
YoY Change	340.0%	400.0%
Cash From Operating Activities	-$52.78M	-$21.38M
YoY Change	146.87%	98.33%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$170.0K
YoY Change	-100.0%	1600.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$830.0K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	-$1.000M
YoY Change	-100.0%	9900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	420.0K	26.81M
YoY Change	-98.43%	110.27%
NET CHANGE
Cash From Operating Activities	-52.78M	-21.38M
Cash From Investing Activities	0.000	-1.000M
Cash From Financing Activities	420.0K	26.81M
Net Change In Cash	-52.36M	4.430M
YoY Change	-1281.94%	126.02%
FREE CASH FLOW
Cash From Operating Activities	-$52.78M	-$21.38M
Capital Expenditures	$0.00	-$170.0K
Free Cash Flow	-$52.78M	-$21.21M
YoY Change	148.84%	96.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Share Price SharePrice	5.80
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	5320000
CY2012Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	120214000
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	250255000
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150752960	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.44
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	20079	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9866826	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150732881	shares
CY2013Q2	us-gaap	Interest Payable Current InterestPayableCurrent	9555000
CY2013Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1448000
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	8600000
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	35434000
CY2013Q2	us-gaap	Senior Long Term Notes SeniorLongTermNotes	141457000
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	86687000
CY2013Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14358000
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9688000
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	795000
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-94334000
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	630565000
CY2013Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	45515000
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-849575000
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1833000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310855000
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5335000
CY2013Q2	us-gaap	Liabilities Liabilities	309001000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	592000
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	124893000
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214667000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4951000
CY2012Q4	us-gaap	Inventory Net InventoryNet	21262000
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	326000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1400000
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2267000
CY2013Q2	us-gaap	Inventory Net InventoryNet	28514000
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13410000
CY2013Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	936000
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5918000
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	217000
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	706000
CY2013Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	12880000
CY2013Q2	us-gaap	Assets Assets	214667000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149426000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11032000
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2171000
CY2013Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8491000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11624000
CY2013Q2	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	695000
CY2013Q2	us-gaap	Assets Current AssetsCurrent	184714000
CY2013Q2	amrn	Cash Discount Percent CashDiscountPercent	0.02	pure
CY2013Q2	amrn	Excess Fair Value Over Principal Value ExcessFairValueOverPrincipalValue	51300000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-5962000
CY2011Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	123125000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116602000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150360933	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	20079	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150340854	shares
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2520000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25202000
CY2012Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	134250000
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	85153000
CY2012Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5224000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17458000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	816000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3997000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	619266000
CY2012Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	69431000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-747643000
CY2012Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	14600000
CY2012Q4	us-gaap	Liabilities Liabilities	314852000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	269000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	124597000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	937000
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5465000
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	217000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	811000
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8044000
CY2012Q4	us-gaap	Assets Assets	310855000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260242000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11355000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3253000
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15471000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11624000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	285694000
	dei	Trading Symbol TradingSymbol	AMRN
	dei	Entity Registrant Name EntityRegistrantName	AMARIN CORP PLC\UK
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000897448
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112416000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	319750	shares
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.94	pure
	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Long Term Debt Redemption Feature</u></i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company’s December 2012 financing agreement with BioPharma Secured Debt Fund II Holdings Cayman, L.P, or BioPharma, contains a redemption feature whereby, upon a change of control, the Company would be required to pay $140 million, less any previously repaid amount, if the change of control occurs on or before December 31, 2013, or required to repay $150 million, less any previously repaid amount, if the change of control event occurs after December 31, 2013. The Company determined this redemption feature to be an embedded derivative, which is carried at fair value and is classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. The fair value of the embedded derivative was calculated using a probability-weighted model incorporating management estimates for potential change in control, and by determining the fair value of the debt with and without the change in control provision included. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative. The fair value of the derivative liability was calculated at both December 31, 2012 and at June 30, 2013. At December 31, 2012, the fair value of the derivative was determined to be $14.6 million, and the debt was valued by comparing debt issues of similar companies with (i) terms of between 4.8 and 8.0 years, (ii) coupon rates of between 3.0% and 11.5% and (iii) market yields of between 10.7% and 27.7%. At June 30, 2013, the fair value of the derivative was determined to be $8.6 million, and the debt was valued by comparing debt issues of similar companies with (i) remaining terms of between 3.8 and 7.1 years, (ii) coupon rates of between 9.9% and 12.5% and (iii) market yields of between 10.8% and 26.0%. The Company recognized a $6.0 million gain on change in fair value of derivative liability for the six months ended June 30, 2013.</font></p> </div>
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17489000
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y1M6D
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.002	pure
	us-gaap	Debt Instrument Call Date Earliest DebtInstrumentCallDateEarliest	2017-01-19
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Use of Estimates</u></i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Actual results could differ from those estimates. The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates.</font></p> </div>
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y3M18D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1400000
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	22461000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	541000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	765000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-536000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18205000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	1003000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1082000
	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	3830000
	us-gaap	Interest Paid InterestPaid	2625000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-105124000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2267000
	us-gaap	Revenues Revenues	7842000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	384000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-108844000
	us-gaap	Gain On Derivative Instruments Pretax GainOnDerivativeInstrumentsPretax	6000000
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1003000
	us-gaap	Net Income Loss NetIncomeLoss	-101932000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7252000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9963000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4131000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4836000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8740000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1614000
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	1003000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-110816000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	3313000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27662000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	7035000
	us-gaap	Interest Expense Debt InterestExpenseDebt	8500000
	us-gaap	Operating Expenses OperatingExpenses	116686000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73228000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3192000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	70000
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	2382000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	541000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	323000
	us-gaap	Direct Operating Costs DirectOperatingCosts	4826000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39327000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18000
	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	150562	shares
	amrn	Product Sales ProductSales	9675000
	amrn	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	70000	shares
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	144316000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2314000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14930000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6678000
	amrn	Proceeds From Stock Option Exercise And Other ProceedsFromStockOptionExerciseAndOther	500000
	amrn	Significant Assumptions In Market Price Of Stock SignificantAssumptionsInMarketPriceOfStock	0.10	pure
	amrn	Stock Issued During Period Of Stock And Warrants For Services Or Claims StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims	18000
	amrn	Cash Discount Invoice Terms CashDiscountInvoiceTerms	P30D
	amrn	Proceeds From Exercise Of Stock Options And Warrants ProceedsFromExerciseOfStockOptionsAndWarrants	100000
	amrn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	70000
	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	500000
	amrn	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	100000
	amrn	Increase Decrease In Lease Related Liabilities IncreaseDecreaseInLeaseRelatedLiabilities	-19000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39122000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2485647	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	92282000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	264000
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-85139000
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	825000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6678000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	313000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8268000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	7960000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4596000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-139875000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5533000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46484000
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	22898000
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	7960000
	us-gaap	Net Income Loss NetIncomeLoss	-142189000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	20000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8709000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6020000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	173864000
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	7960000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	75000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	133653000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	14505000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2508000
	us-gaap	Operating Expenses OperatingExpenses	46484000
	amrn	Proceeds From Stock Option Exercise And Other ProceedsFromStockOptionExerciseAndOther	6700000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1089000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18822000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	14000
	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	138280	shares
	amrn	Derivative Liabilities Transferred To Stockholders Equity DerivativeLiabilitiesTransferredToStockholdersEquity	92282000
	amrn	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	9812622	shares
	amrn	Stock Issued During Period Of Stock And Warrants For Services Or Claims StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims	14000
	amrn	Proceeds From Exercise Of Stock Options And Warrants ProceedsFromExerciseOfStockOptionsAndWarrants	14900000
	amrn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	14930000
	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	6700000
	amrn	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	15000000
	amrn	Reclassification Of Derivative Liabilities To Additional Paid In Capital ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital	92282000
	amrn	Increase Decrease In Lease Related Liabilities IncreaseDecreaseInLeaseRelatedLiabilities	-46000
CY2012Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.00	pure
CY2012	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2012	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0025	pure
CY2012	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y9M18D
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2012Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-18930000
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-52000
CY2012Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4317000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-51000000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-27701000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-53904000
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	27701000
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13635000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2904000
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14066000
CY2012Q2	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	140550	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	18841000
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-411000
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9345000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-39709000
CY2013Q2	us-gaap	Revenues Revenues	5500000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-48794000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-39774000
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2844000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	54294000
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33961000
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000
CY2013Q2	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	150694	shares

Files In Submission

Name	View Source	Status
0001193125-13-326829-index-headers.html	Edgar Link	pending
0001193125-13-326829-index.html	Edgar Link	pending
0001193125-13-326829.txt	Edgar Link	pending
0001193125-13-326829-xbrl.zip	Edgar Link	pending
amrn-20130630.xml	Edgar Link	completed
amrn-20130630.xsd	Edgar Link	pending
amrn-20130630_cal.xml	Edgar Link	unprocessable
amrn-20130630_def.xml	Edgar Link	unprocessable
amrn-20130630_lab.xml	Edgar Link	unprocessable
amrn-20130630_pre.xml	Edgar Link	unprocessable
d543388d10q.htm	Edgar Link	pending
d543388dex31.htm	Edgar Link	pending
d543388dex311.htm	Edgar Link	pending
d543388dex312.htm	Edgar Link	pending
d543388dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRN
AMARIN CORP PLC\UK Stock $amrn

2013 Q2 Form 10-Q Financial Statement

#000119312513326829 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN AMARIN CORP PLC\UK Stock $amrn

2013 Q2 Form 10-Q Financial Statement

#000119312513326829 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN
AMARIN CORP PLC\UK Stock $amrn